PDL BioPharma, Inc. P/B ratio

P/B ratio of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of PDL BioPharma, Inc. is 0.65 (as of December 30, 2019)
  • P/B ratio for the quarter ending June 29, 2020 was 0.74 (a 54.4% increase compared to previous quarter)
  • Year-over-year quarterly P/B ratio increased by 94.12%
  • Annual P/B ratio for 2019 was 0.65 (a 12.09% increase from previous year)
  • Annual P/B ratio for 2018 was 0.58 (a 9.81% increase from previous year)
  • Annual P/B ratio for 2017 was 0.53 (a 9.02% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of PDL BioPharma, Inc.

Most recent P/B ratioof PDLI including historical data for past 10 years.

Interactive Chart of P/B ratio of PDL BioPharma, Inc.

PDL BioPharma, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.74 0.48
2019 0.65 0.38 0.55 0.69 0.65
2018 0.58 0.49 0.5 0.52 0.58
2017 0.53 0.62 0.47 0.49 0.53
2016 0.48 0.73 0.7 0.73 0.48
2015 0.83 1.38 1.99 2.53 0.83
2014 2.65 2.98 5.23 6.21 2.65
2013 10.4 21.07 0.0 0.0 10.4
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0 0.0 0.0 0.0
2010 0.0 0.0 0.0 0.0

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.